Nordic Drugs has developed very successfully over the last ten years via mainly organic growth. Today, Nordic Drugs is one of the leading speciality pharma companies in the Nordic region. The continued growth will come from licensing of added value products and NME:s as well as from acquisitions.
As part of the fast expanding, fully integrated pan-European pharmaceutical company ‘The Nordic Group’, our ability to in-license and develop our own products has dramatically increased, guaranteeing a continued strong growth and market presence. As a privately held group, we employ a long-term strategy in our investments and expansion plans.
Nordic Drugs will during the coming years bring forward several new products to the Nordic market, securing a high growth rate and increased market share. We will continue to build on the very firm ground we have established over more than a decade as a leading player in the Nordic market.
Anders Löfgren, CEO